Circulating nedd9 is increased in pulmonary arterial hypertension
AssigneeThe Brigham and Women S Hospital, Inc.
InventorsBradley A. Maron, Andriy Samokhin, George A. Alba
Life of this patent
Estimating the term…
Abstract
Aspects of the present disclosure relate to methods for detecting neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9) in a sample from a subject having or at risk for pulmonary hypertension (PH), wherein pulmonary hypertension (PH) is selected from the group consisting of pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and pulmonary hypertension (PH) due to acute respiratory distress syndrome (ARDS).
Claims20
A method for analyzing a sample, the method comprising:
- providing a sample from a subject, and
- detecting neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9) in the sample.
A method of diagnosing a subject as having pulmonary hypertension (PH), the method comprising:
- providing a sample from the subject,
- detecting a level of NEDD9 in the sample;
- and
- comparing the level of NEDD9 in the sample to a reference level, wherein the presence of a level of NEDD9 in the sample that is above the reference level indicates that the subject has PH.
Dependencies are inferred from the claim text.